These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31825965)

  • 1. The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study.
    Lee EC; Azman AS; Kaminsky J; Moore SM; McKay HS; Lessler J
    PLoS Med; 2019 Dec; 16(12):e1003003. PubMed ID: 31825965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study.
    Azman AS; Luquero FJ; Ciglenecki I; Grais RF; Sack DA; Lessler J
    PLoS Med; 2015 Aug; 12(8):e1001867. PubMed ID: 26305226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
    Schaetti C; Weiss MG; Ali SM; Chaignat CL; Khatib AM; Reyburn R; Duintjer Tebbens RJ; Hutubessy R
    PLoS Negl Trop Dis; 2012; 6(10):e1844. PubMed ID: 23056660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Cholera Vaccination Delivery Cost in Low- and Middle-Income Countries: An Analysis Based on Systematic Review.
    Mogasale V; Ramani E; Wee H; Kim JH
    PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005124. PubMed ID: 27930668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.
    Murray J; McFarland DA; Waldman RJ
    Bull World Health Organ; 1998; 76(4):343-52. PubMed ID: 9803585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study.
    Lee EC; Chao DL; Lemaitre JC; Matrajt L; Pasetto D; Perez-Saez J; Finger F; Rinaldo A; Sugimoto JD; Halloran ME; Longini IM; Ternier R; Vissieres K; Azman AS; Lessler J; Ivers LC
    Lancet Glob Health; 2020 Aug; 8(8):e1081-e1089. PubMed ID: 32710864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh.
    Khan AI; Khan IA; Siddique SA; Rahman A; Islam MT; Bhuiya MAI; Saha NC; Biswas PK; Saha A; Chowdhury F; Qadri F
    Hum Vaccin Immunother; 2019; 15(6):1302-1309. PubMed ID: 30261152
    [No Abstract]   [Full Text] [Related]  

  • 8. Mapping the burden of cholera in sub-Saharan Africa and implications for control: an analysis of data across geographical scales.
    Lessler J; Moore SM; Luquero FJ; McKay HS; Grais R; Henkens M; Mengel M; Dunoyer J; M'bangombe M; Lee EC; Djingarey MH; Sudre B; Bompangue D; Fraser RSM; Abubakar A; Perea W; Legros D; Azman AS
    Lancet; 2018 May; 391(10133):1908-1915. PubMed ID: 29502905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis.
    Khan AI; Levin A; Chao DL; DeRoeck D; Dimitrov DT; Khan JAM; Islam MS; Ali M; Islam MT; Sarker AR; Clemens JD; Qadri F
    PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006652. PubMed ID: 30300420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study.
    Finger F; Bertuzzo E; Luquero FJ; Naibei N; Touré B; Allan M; Porten K; Lessler J; Rinaldo A; Azman AS
    PLoS Med; 2018 Feb; 15(2):e1002509. PubMed ID: 29485987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral cholera vaccine delivery strategy in India: Routine or campaign?-A scoping review.
    Ray A; Sarkar K; Haldar P; Ghosh R
    Vaccine; 2020 Feb; 38 Suppl 1():A184-A193. PubMed ID: 31377080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical Modeling of Endemic Cholera Transmission.
    Chao DL
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S738-S741. PubMed ID: 34550373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to an outbreak and floods in Malawi.
    Msyamboza KP; M'bang'ombe M; Hausi H; Chijuwa A; Nkukumila V; Kubwalo HW; Desai S; Pezzoli L; Legros D
    Pan Afr Med J; 2016; 23():203. PubMed ID: 27347292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study.
    Khatib AM; Ali M; von Seidlein L; Kim DR; Hashim R; Reyburn R; Ley B; Thriemer K; Enwere G; Hutubessy R; Aguado MT; Kieny MP; Lopez AL; Wierzba TF; Ali SM; Saleh AA; Mukhopadhyay AK; Clemens J; Jiddawi MS; Deen J
    Lancet Infect Dis; 2012 Nov; 12(11):837-44. PubMed ID: 22954655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis.
    Naficy A; Rao MR; Paquet C; Antona D; Sorkin A; Clemens JD
    JAMA; 1998 Feb; 279(7):521-5. PubMed ID: 9480362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholera and COVID-19 pandemic prevention in multiple hotspot districts of Uganda: vaccine coverage, adverse events following immunization and WASH conditions survey.
    Bwire G; Kisakye A; Amulen E; Bwanika JB; Badebye J; Aanyu C; Nakirya BD; Okello A; Okello SA; Bukenya JN; Orach CG
    BMC Infect Dis; 2023 Jul; 23(1):487. PubMed ID: 37479986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral cholera vaccination coverage in an acute emergency setting in Somalia, 2017.
    Lubogo M; Mohamed AM; Ali AH; Ali AH; Popal GR; Kiongo D; Bile KM; Malik M; Abubakar A
    Vaccine; 2020 Feb; 38 Suppl 1():A141-A147. PubMed ID: 31980193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cholera surveillance to improve vaccination campaign efficiency.
    Xu H; Zou K; Dent J; Wiens KE; Malembaka EB; Bwire G; Okitayemba PW; Hampton LM; Azman AS; Lee EC
    Nat Med; 2024 Apr; 30(4):1104-1110. PubMed ID: 38443690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.
    Cookson ST; Stamboulian D; Demonte J; Quero L; Martinez de Arquiza C; Aleman A; Lepetic A; Levine MM
    Int J Epidemiol; 1997 Feb; 26(1):212-9. PubMed ID: 9126522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of and challenges for cholera vaccines in Africa.
    von Seidlein L; Jiddawi M; Grais RF; Luquero F; Lucas M; Deen J
    J Infect Dis; 2013 Nov; 208 Suppl 1():S8-14. PubMed ID: 24101650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.